Bristol-Myers Squibb Company (BMY) AGM 2026 summary

Opening remarks and agenda

• The meeting was called to order with all board members and key leadership present, and a quorum representing over 86% of shares established.

• Shareholders were welcomed and informed about the agenda, voting procedures, and technical support for the virtual meeting.

Financial performance review

• Total revenues for 2025 reached $48.2 billion, with the growth portfolio accounting for over half and increasing 17% from 2024.

• Three products surpassed $1 billion in sales, and REBLOZYL exceeded $2 billion.

• Despite a $4 billion decline in legacy portfolio revenue, growth portfolio nearly offset the loss.

• Achieved $10 billion debt paydown ahead of schedule and marked the 93rd consecutive year of dividend payments.

Board and executive committee updates

• All board members up for re-election were present, and the board's lead audit partner from Deloitte & Touche LLP attended.